Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

BNOX - Bionomics Ltd. - ADR


IEX Last Trade
0.6425
-0.001   -0.171%

Share volume: 98,696
Last Updated: Fri 30 Aug 2024 09:58:17 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.64
0.00
-0.17%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-5.07%
1 Month
-22.97%
3 Months
-34.96%
6 Months
-48.39%
1 Year
-61.53%
2 Year
-91.66%
Key data
Stock price
$0.64
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$0.50 - $6.41
52 WEEK CHANGE
-$0.67
MARKET CAP 
7.678 M
YIELD 
N/A
SHARES OUTSTANDING 
11.951 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.81
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$115,676
AVERAGE 30 VOLUME 
$234,210
Company detail
CEO:
Region: US
Website: http://www.bionomics.com.au
Employees: 33
IPO year: -
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

bionomics is a biopharmaceutical company dedicated to making better treatments for cancer, central nervous system disorders such as anxiety, depression and alzheimer's disease. our exceptionally talented team is driven by a shared commitment to make a difference in diseases with inadequate treatment options. we are in a strong growth phase with our world-class portfolio of promising drug candidates from early to advanced stages of clinical development. this portfolio is fed by highly productive drug discovery platforms which includes multicore®, our proprietary chemistry capability. at the core of our business is strategic partnering. we partner with large pharmaceutical companies to get our drugs through the later stages of development and into the market as rapidly as possible. this means we can focus our strengths in innovative drug discovery to extract as many "shots on goal"​ from our diverse pipeline in the quest to create the world's new blockbuster drugs. we have a passion for

Recent news